Mitsubishi Tanabe Pharma America Mitsubishi Tanabe Pharma America - Mobile
  • Home
  • About Us
  • Science
  • Therapeutic Areas
  • Our People
  • News
  • Our Compliance Program
  • Contact Us
  • Resources
  • Careers
  • Global Site
  • Mitsubishi Tanabe Pharma America Announces Nearly 4,000 ALS Patients in the U.S. Have Been Treated with RADICAVA ORS® (edaravone)

  • Mitsubishi Tanabe Pharma America Announces Presentations at Virtual 33rd International Symposium on ALS/MND

  • Mitsubishi Tanabe Pharma America Presents Interim Data from REFINE-ALS Biomarker Study at 21st Annual NEALS Meeting

  • Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Data at 21st Annual NEALS Meeting

  • Mitsubishi Tanabe Pharma America Celebrates Nearly 2,000 ALS Patients treated with RADICAVA ORS® (edaravone)

  • Mitsubishi Tanabe Pharma America Presents Data on RADICAVA ORS® (edaravone) at 2022 AANEM Annual Meeting

  • Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Survival with RADICAVA® (edaravone)

  • Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (edaravone)

  • RADICAVA ORS® (edaravone) Now Available in the U.S. for the Treatment of ALS

  • Mitsubishi Tanabe Pharma America Presents 48-Week Results from Global Phase 3 Safety Clinical Study of RADICAVA ORS® (edaravone), an Oral Treatment for ALS

Mitsubishi Tanabe Pharma America
OUR COMPANY
  • About Us
  • Science
  • Therapeutic Areas
  • Our People
RESOURCES
  • Medical Inquiries
  • Our Compliance Program
  • Educational Grants
  • Sponsorships
  • Charitable Contributions
  • Investigator Initiated Trials (IITs)
MEDIA
  • News
  • Press Kit
CONNECT WITH US
  • Facebook
  • Twitter
  • LinkedIn
  • COVID-19
  • Global Site
  • Contact Us
  • Careers
  • Terms of Use
  • Our Compliance Program
  • Privacy Policy
  • Expanded Access Policy
  • Our Policies
© Mitsubishi Tanabe Pharma America 2023      CP-MTPA-US-0205 08/22